JAZZ - Jazz Pharmaceuticals, Inc. - Page 9

someone explain to me why JAZZ isnt trading

FDA stuff going on...probably trading halted pending news

Shareholder? Short?

you think this new drugs gonna pass? everywhere i read it says theres a good chance it will

what?

no telling.....FDA is kind of like dealing with a schizo....

he's asking: did you buy the stock or did you short it?

ohh , yeah im just watching it, i dont have an open position.

oldfart, is there any way you can spy on the FDA, know the outcome sooner than everyone else ;p

don't think so...

Here is a live blog of the panel if you are interested

http://www.thestreet.com/story/10840...live-blog.html

wow thats very interesting, do other developing stories have a live blog?

Drug denied trading still halted

2 yes, 20 no. Sell off AH.

OH SHIT OWNED!

i was p.o.'d at myself for taking my profit last week. hope you guys are ok.

this is where you'd want an options collar...

sell a call ATM couple months out
use that money to buy a cheap put OTM next month
pocket the difference

Not bad to bad I didnt keep my shares when I was trading pennys on this LOL

I cant believe I bought 2000 shares of this stock back in august 23 2010 for the price of 7.78 a piece! and sold it under $8! fcuk!

could have made 25k in 3-4 months!

Jazz Pharmaceuticals Announces Second Quarter 2011 Financial Results
3 days 4 hours 9 minutes ago - PR Newswire via Comtex
PR Newswire

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the second quarter of 2011.

Total revenues for the quarter ended June 30, 2011 were $64.6 million, compared to $40.5 million for the second quarter of 2010. Total revenues included net product sales, royalties and contract revenues.

GAAP net income for the second quarter of 2011 was $33.2 million, or $0.71 per diluted share, compared to a GAAP net loss of $6.4 million, or $0.18 per diluted share, for the second quarter of 2010. The company's GAAP net loss in the second quarter of 2010 included a loss on extinguishment of debt of $12.3 million.

Adjusted net income for the second quarter of 2011 was $38.4 million, or $0.82 per diluted share, compared to $10.5 million, or $0.28 per diluted share, for the second quarter of 2010. A reconciliation of GAAP net income (loss) to adjusted net income and the related per diluted share amounts is included with this press release.

Net sales of Xyrem® (sodium oxybate) oral solution increased 67 percent to $56.2 million for the second quarter of 2011, compared to net sales of $33.7 million for the second quarter of 2010. Net sales of once-daily Luvox CR® (fluvoxamine maleate) were $7.3 million for the second quarter of 2011, compared to $5.8 million for the prior year period, an increase of 26 percent.

"Our strong quarterly performance demonstrates our ongoing commitment to growing Xyrem as the core of our company's strategy," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "We were also pleased to prepay the remaining $33 million of our long-term debt on July 1, further strengthening our balance sheet as our cash position continues to grow."

Selling, general and administrative expenses and research and development expenses combined for the second quarter of 2011 were $25.5 million, compared to $25.1 million for the second quarter of 2010, reflecting higher headcount related expenses, including stock-based compensation, increased legal expenses, and lower product development spending.

Balance Sheet Update

As of June 30, 2011, cash and cash equivalents were $102.4 million. On July 1, 2011, the company paid in full the $33.3 million principal amount of its term loan and a prepayment penalty of $0.3 million.

Jazz Pharmaceuticals Raises Guidance
3 days 3 hours 19 minutes ago - EarningsWhispers Earnings Guidance via Comtex
EarningsWhispers Earnings Guidance



Jazz Pharmaceuticals Inc (NASDAQ: JAZZ) said it now expects 2011 non-GAAP earnings of $3.15 to $3.25 per share on revenue of $247.0 million to $260.0 million. The company's previous guidance was earnings of $2.95 to $3.10 per share on revenue of $237.0 million to $250.0 million and the current consensus earnings estimate is $3.07 per share on revenue of $250.2 million for the year ending December 31, 2011.